ANGN: AI 评分 44/100 — AI 分析 (4月 2026)

Angion Biomedica Corp. is a biopharmaceutical company focused on developing therapies for acute organ injuries and fibrotic diseases. Their lead product candidate, ANG-3070, targets fibrotic diseases affecting the kidney and lung.

Key Facts: Price: $1.00 AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Angion Biomedica pioneers innovative small molecule therapeutics for acute organ injuries and fibrotic diseases, highlighted by ANG-3070's potential in treating kidney and lung fibrosis, positioning the company at the forefront of regenerative medicine with a focused pipeline and experienced leadership.

ANGN是做什么的？

Angion Biomedica Corp., founded in 1998 and headquartered in Uniondale, New York, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel small molecule therapeutics. The company focuses on addressing significant unmet medical needs in acute organ injuries and fibrotic diseases, conditions characterized by tissue scarring and organ dysfunction. Angion's lead product candidate, ANG-3070, is an oral tyrosine kinase receptor inhibitor currently in development as a treatment for fibrotic diseases, with a primary focus on the kidney and lung. This innovative therapy aims to halt or reverse the progression of fibrosis, offering potential benefits to patients suffering from these debilitating conditions. In addition to ANG-3070, Angion is also developing ANG-3777, a hepatocyte growth factor mimetic designed to treat acute organ injuries, including delayed graft function following organ transplantation. The company's pipeline also includes ROCK2 inhibitors programs for fibrotic diseases and a CYP11B2 inhibitor program, further demonstrating its commitment to addressing a wide range of organ-related diseases. Angion's strategic focus on small molecule therapeutics allows for oral administration and potential systemic delivery, offering advantages over other treatment modalities. The company's experienced management team and scientific advisors bring a wealth of expertise in drug development and commercialization, positioning Angion as a key player in the biopharmaceutical landscape.

ANGN的投资论点是什么？

Angion Biomedica presents a notable market position due to its focused pipeline targeting significant unmet needs in fibrotic diseases and acute organ injuries. The lead candidate, ANG-3070, holds substantial promise in treating kidney and lung fibrosis, with potential to capture a significant share of the growing market for anti-fibrotic therapies. The company's ANG-3777, targeting acute organ injuries, adds diversification and further growth potential. With a market capitalization of $0.03 billion, Angion offers significant upside potential if clinical trials are successful. Key value drivers include positive clinical trial data for ANG-3070, potential partnerships or licensing agreements, and eventual FDA approval. the may be worth researching inherent risks of biotech investing, including clinical trial failures and regulatory hurdles, but the potential rewards justify the risk.

ANGN在哪个行业运营？

Angion Biomedica operates within the biotechnology industry, which is characterized by high innovation, intense competition, and significant regulatory oversight. The market for therapies targeting fibrotic diseases is expanding due to the increasing prevalence of chronic conditions such as kidney disease and pulmonary fibrosis. Key competitors include companies like ALNA, AMHV, CHRO, CWBR, and EMMLF, which are also developing therapies for similar indications. The biotechnology industry is driven by scientific advancements, clinical trial outcomes, and regulatory approvals, making it a high-risk, high-reward sector.

Biotechnology

Healthcare

ANGN有哪些增长机遇？

ANG-3070 Development in Kidney Fibrosis: The market for kidney fibrosis treatments is estimated to reach billions of dollars in the coming years. Positive Phase 2/3 trial results for ANG-3070 could lead to FDA approval within 3-5 years, driving significant revenue growth for Angion. The competitive advantage lies in ANG-3070's oral administration and targeted mechanism of action.
ANG-3070 Development in Lung Fibrosis: Similar to kidney fibrosis, the lung fibrosis market presents a substantial opportunity. Successful clinical trials and regulatory approval for ANG-3070 in lung fibrosis could further expand the company's revenue streams. The timeline for approval is estimated at 3-5 years, contingent on clinical trial outcomes.
ANG-3777 for Acute Organ Injuries: ANG-3777 targets acute organ injuries, including delayed graft function, a significant complication following organ transplantation. Positive clinical trial data could lead to regulatory approval and market adoption within 2-4 years. This represents a niche market with potential for high pricing and profitability.
Partnerships and Licensing Agreements: Angion can pursue partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These agreements can provide upfront payments, milestone payments, and royalties, boosting the company's financial resources and market reach. The timeline for securing such agreements is variable but could occur within the next 1-2 years.
Expansion of Pipeline: Angion can expand its pipeline through internal research and development or through acquisitions of other companies or assets. This would diversify the company's risk profile and create additional growth opportunities. The timeline for pipeline expansion is dependent on the availability of suitable opportunities and the company's financial resources.

Market Cap of $0.03 billion indicates a micro-cap stock with potential for high growth but also higher volatility.
P/E ratio of -0.27 reflects the company's current lack of profitability, common for development-stage biopharmaceutical companies.
Lead product candidate ANG-3070 targets a multi-billion dollar market in fibrotic diseases.
ANG-3777 offers potential in treating acute organ injuries, diversifying the pipeline.
The company's small size and focused pipeline makes it a potential acquisition target for larger pharmaceutical companies.

ANGN提供哪些产品和服务？

Develop small molecule therapeutics for acute organ injuries.
Focus on treatments for fibrotic diseases.
Lead product candidate: ANG-3070, an oral tyrosine kinase receptor inhibitor.
Developing ANG-3777, a hepatocyte growth factor mimetic.
Researching ROCK2 inhibitors for fibrotic diseases.
Exploring CYP11B2 inhibitors.

ANGN如何赚钱？

Discovering and developing novel drug candidates.
Conducting preclinical and clinical trials.
Seeking regulatory approval from agencies like the FDA.
Potentially commercializing products directly or through partnerships.
Generating revenue through product sales, licensing agreements, and milestone payments.

Patients suffering from fibrotic diseases (kidney, lung).
Patients with acute organ injuries.
Hospitals and transplant centers.
Potential pharmaceutical partners for licensing and collaboration.

Proprietary small molecule therapeutics.
Patent protection for drug candidates.
Expertise in drug development and clinical trials.
Focus on unmet medical needs in specific disease areas.

什么因素可能推动ANGN股价上涨？

Upcoming: Phase 2/3 clinical trial data release for ANG-3070 in kidney fibrosis.
Upcoming: Phase 2 clinical trial data release for ANG-3070 in lung fibrosis.
Upcoming: Potential partnership or licensing agreement announcement.
Ongoing: Continued progress in clinical development of ANG-3777.
Ongoing: Advancements in ROCK2 and CYP11B2 inhibitor programs.

ANGN的主要风险是什么？

Potential: Clinical trial failures for ANG-3070 or ANG-3777.
Potential: Regulatory delays or rejection of drug candidates.
Ongoing: Competition from other companies developing similar therapies.
Ongoing: Need for additional financing, potentially diluting existing shareholders.
Potential: Dependence on key personnel and scientific advisors.

ANGN的核心优势是什么？

Focused pipeline targeting unmet medical needs.
Proprietary small molecule therapeutics.
Experienced management team.
Potential for significant revenue growth if clinical trials are successful.

ANGN的劣势是什么？

Limited financial resources.
Dependence on clinical trial outcomes.
High risk of drug development failure.
Small market capitalization makes it vulnerable to volatility.

ANGN有哪些机遇？

Partnerships and licensing agreements.
Expansion of pipeline through acquisitions.
Positive clinical trial data leading to regulatory approval.
Growing market for fibrotic disease treatments.

ANGN面临哪些威胁？

Competition from larger pharmaceutical companies.
Clinical trial failures.
Regulatory hurdles.
Dilution of existing shareholders through future financing.

ANGN的竞争对手是谁？

Allena Pharmaceuticals, Inc. — Focuses on metabolic disorders affecting the kidney. — (ALNA)
American Health Ventures, Inc. — Unknown specific therapeutic focus. — (AMHV)
Chromadex Corp. — Focuses on dietary supplements and ingredients. — (CHRO)
Cowen Healthcare Royalty — Healthcare royalty and investment firm. — (CWBR)
Emmis Communications Corp. — Media and broadcasting company. — (EMMLF)

Key Metrics

Price: $1.00 (+910.10%)
Market Cap: $31.0M
MoonshotScore: 44/100

常见问题

What does Angion Biomedica Corp. (ANGN) do?

Angion Biomedica Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule therapeutics to treat acute organ injuries and fibrotic diseases. Their lead product candidate, ANG-3070, is an oral tyrosine kinase receptor inhibitor in development for fibrotic diseases, primarily affecting the kidney and lung. The company also develops ANG-3777, a hepatocyte growth factor mimetic for acute organ injuries, showcasing their commitment to addressing unmet medical needs in organ-related diseases.

Is ANGN stock a good buy?

ANGN stock presents a high-risk, high-reward investment opportunity. With a market cap of $0.03 billion, it's a micro-cap stock with significant growth potential if ANG-3070's clinical trials are successful. However, the company's negative P/E ratio and dependence on clinical trial outcomes highlight the risks. Investors should carefully weigh the potential upside against the inherent risks of biotech investing before considering ANGN a good buy.

What are the risks of investing in ANGN?

Investing in ANGN carries several risks, including the potential for clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies. The company's limited financial resources necessitate additional financing, potentially diluting existing shareholders. Given the nature of biotechnology, there's a risk that ANG-3070 or ANG-3777 may not achieve regulatory approval, impacting the company's future prospects and stock value.

What catalysts could move ANGN stock?

Several catalysts could move ANGN stock, including positive Phase 2/3 clinical trial data for ANG-3070 in kidney fibrosis and Phase 2 data in lung fibrosis. An announcement of a partnership or licensing agreement with a larger pharmaceutical company could also boost investor confidence. Continued progress in the clinical development of ANG-3777 and advancements in the ROCK2 and CYP11B2 inhibitor programs could further drive stock movement.

What is ANGN stock price target?

As of 2026-03-03, there is no readily available analyst consensus price target for ANGN stock, likely due to its micro-cap status and speculative nature. A fair value estimate would require a detailed discounted cash flow analysis, considering the potential revenue from ANG-3070 and ANG-3777, discounted by the high risk associated with clinical-stage biopharmaceutical companies. Investors should conduct their own due diligence to determine a suitable price target.